Trial Profile

A clinical trial of BIIB 142 for treatment of autoimmune diseases

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Oct 2025 New trial record
04 Sep 2025 According to a C4 Therapeutics media release, the company announced that its partner, Biogen, has received U.S. Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for BIIB142. Biogen will lead all future clinical development and commercialization activities, with C4 Therapeutics set to receive a $2 million milestone payment upon the initiation of patient dosing in the BIIB142 clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com